16:42 , Jul 20, 2018 |  BC Week In Review  |  Company News

Novartis halts price increases, reports 2Q earnings

Novartis AG (NYSE:NVS; SIX:NOVN) announced on July 18 that it will suspend for the rest of the year price increases in the U.S. The pharma made the announcement in conjunction with the release of its 2Q18...
19:59 , Jul 18, 2018 |  BC Extra  |  Company News

Novartis halts price increases, reports 2Q earnings

Novartis AG (NYSE:NVS; SIX:NOVN) announced Wednesday that it will suspend for the rest of the year price increases in the U.S. The pharma made the announcement in conjunction with the release of its 2Q18 earnings. On...
18:21 , Jun 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer, sarcoma Cell culture studies suggest inhibiting IFT88 or SCLT1 could help treat kinase inhibitor-resistant lung cancer and rhabdomyosarcoma. In a human EGFR inhibitor-resistant non-small cell lung cancer (NSCLC) cell line, the EGFR inhibitor...
23:00 , Jun 7, 2018 |  BC Extra  |  Preclinical News

Targeting tumor cilia could reverse resistance to kinase inhibitors

A Cell Reports study from Institute of Cancer Research (ICR) researchers and colleagues identified cilia on tumor cells as a new, potentially universal target for sensitizing drug-resistant cells to kinase inhibitors. The research suggests inhibiting...
23:20 , Mar 27, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer; inflammation

INDICATION: Colorectal cancer; asthma Mouse and cell culture studies identified a RIPK2-inhibiting analog of Iclusig ponatinib that could help treat colorectal cancer and asthma. In silico screening of Iclusig analogs for RIPK2 binding and in vitro...
00:00 , Jan 18, 2018 |  BioCentury  |  Emerging Company Profile

Computing brain entry

1st Biotherapeutics Inc. aims to develop a pipeline of first- or best-in-class molecules for CNS diseases by using computational tools to achieve better blood-brain barrier penetration and PK properties than marketed drugs against the same...
23:12 , Jan 3, 2018 |  BC Week In Review  |  Clinical News

Novartis' Tasigna gets treatment-free remission FDA label expansion

FDA updated the label of Tasigna nilotinib from Novartis AG (NYSE:NVS; SIX:NOVN) to reflect that some chronic myelogenous leukemia (CML) patients could be eligible to stop treatment after achieving a sustained response. The BCR-ABL tyrosine kinase...
20:27 , Dec 26, 2017 |  BC Extra  |  Company News

FDA approves treatment-free remission label update for Tasigna

FDA updated the label of Tasigna nilotinib from Novartis AG (NYSE:NVS; SIX:NOVN) to reflect that some chronic myelogenous leukemia (CML) patients could be eligible to stop treatment after achieving a sustained response. The BCR-ABL tyrosine kinase...
23:20 , Dec 14, 2017 |  BC Innovations  |  Product R&D

Opening doors in PML

An NIH-led team has demonstrated that neutralizing antibodies can prevent infection of cells by mutant strains of JCV -- the virus responsible for the lethal brain infection PML. In a field with no clinical options,...
00:49 , Nov 10, 2017 |  BC Innovations  |  Product R&D

Blueprint gets the GIST

Blueprint is positioning its kinase inhibitor BLU-285 to take a dominant position in gastrointestinal tumors, with preclinical and Phase I data showing the compound inhibits not only mutant forms of c-Kit and PDGFRA that underlie...